Emerging Company Profile
Vigil: restoring the vigilance of microglia
Emerging Company Profile: After debuting with $50M, Atlas’ Vigil plans to pursue rare microgliopathies with assets from Amgen
The Atlas incubated biotech will use its $50 million series A to advance in-licensed assets from Amgen in rare genetic disorders that affect the brain’s white matter.
Dec 17, 2020 | 2:44 PM GMT
Incubated by Atlas Venture